Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ImmTOR in combination with Treg-selective IL-2 mutant protein (IL-2 “mutein”) demonstrate substantial synergistic activity in increasing percentage and durability of Treg expansion for treatment of autoimmune diseases and other deleterious immune conditions.
Lead Product(s): IL-2 Mutein
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2021